Moderate

Obstructive sleep apnoea / adenotonsillar hypertrophy

ENT · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Recurrent upper airway obstruction during sleep, most often from adenotonsillar hypertrophy, causing snoring, witnessed apnoeas and disturbed sleep. Untreated, it harms growth, behaviour and cardiovascular health.

Red flags

  • Witnessed apnoeas with cyanosis or severe desaturations on oximetry
  • Failure to thrive or developmental/behavioural regression
  • Signs of pulmonary hypertension / cor pulmonale
  • High-risk child (under 2, Down syndrome, neuromuscular) with significant OSA

Assessment

Differential diagnosis

  • Adenotonsillar hypertrophy (commonest)
  • Obesity-related OSA
  • Craniofacial anomalies (e.g. Pierre Robin, Down syndrome)
  • Neuromuscular hypotonia
  • Allergic rhinitis / nasal obstruction
  • Laryngomalacia (younger infants)
  • Primary (simple) snoring without obstruction

Investigations

  • History of snoring, witnessed apnoeas, restless sleep, mouth breathing and daytime symptoms
  • Examination of tonsil size, adenoidal facies, growth and signs of right heart strain
  • Overnight pulse oximetry as a screening tool
  • Polysomnography where available or diagnosis uncertain / high-risk child
  • Growth parameters and blood pressure
  • ECG/echocardiography if cor pulmonale suspected

Management

  • Take a focused sleep and daytime symptom history and quantify severity
  • Examine tonsils/adenoids, craniofacial structure, weight and cardiovascular status
  • Arrange overnight oximetry or polysomnography to confirm and grade OSA
  • Identify high-risk groups (under 2, Down syndrome, obesity, neuromuscular, craniofacial)
  • Refer high-risk or significant cases to ENT and/or sleep service
  • Offer adenotonsillectomy as first-line for adenotonsillar hypertrophy
  • Treat contributing allergic rhinitis with intranasal corticosteroid
  • Consider CPAP for persistent OSA or when surgery is unsuitable
  • Manage obesity and arrange post-treatment review of symptoms

Drugs & doses

Intranasal corticosteroid (e.g. mometasone 50 microgram per nostril once daily) for mild OSA/allergic component
Montelukast 4-5 mg PO nocte as adjunct for mild OSA/residual symptoms
No specific drug cures OSA; definitive treatment is usually surgical

Disposition

ENT/sleep service referral; expedite for high-risk children or severe desaturations. Post-op inpatient monitoring for high-risk groups.

Complications & pitfalls

  • Pulmonary hypertension and cor pulmonale
  • Growth faltering and neurocognitive/behavioural impairment
  • Post-operative respiratory compromise (high-risk children need inpatient monitoring)
  • Persistent OSA requiring ongoing CPAP

Exam pearls

  • Snoring with pauses and effortful breathing is OSA until proven otherwise, not simple snoring
  • High-risk children should be admitted for monitoring after adenotonsillectomy
  • Obesity is an increasingly important and reversible contributor
  • Adenotonsillectomy resolves most childhood OSA from adenotonsillar hypertrophy

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.